Sagimet Biosciences Inc. (SGMT) is a Biotechnology company in the Healthcare sector, currently trading at $5.54. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Analyst consensus target is SGMT = $8 (+44.4% upside).
Valuation: SGMT trades at a trailing Price-to-Earnings (P/E) of -3.5 (S&P 500 average ~25).
Net income is $51M (loss), growing at -22.3%/yr. Net profit margin is 0% (thin). Gross margin is 100% (+0 pp trend).
Balance sheet: total debt is $78,000 against $111M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 22.82 (strong liquidity). Debt-to-assets is 0.1%. Total assets: $116M.
Analyst outlook: 5 / 6 analysts rate SGMT as buy (83%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 90/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 46/100 (Partial), Future 94/100 (Pass), Income ?/100 (Fail).
